… AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, … therapy in patients with somatostatin receptor 2 expressing … Treatment Drugs Merkel Cell Carcinoma Companies ImmunityBio, OncoSec Medical, … coverage of Clinical Trials, regulatory trends, …

Panelists discuss how cabozantinib showed promising activity in the challenging well-differentiated grade 3 neuroendocrine tumor (NET) population (around 25% response rate), offering a nonchemotherapy option for these aggressive tumors that often lack …

… About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused … once-daily, oral, selective somatostatin receptor type 2 (SST2) … entities resulting from in-house drug discovery efforts, including additional …

… About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused … once-daily, oral, selective somatostatin receptor type 2 (SST2) … entities resulting from in-house drug discovery efforts, including additional …

… fill treatment gaps for patients who have exhausted standard therapies like somatostatin … for healthy patients seeking additional treatment lines in this indolent but …

… health care providers, biotechnology, and underweight to … trials in acromegaly and has a Prescription Drug … doctor and a patient discussing the success of the clinical trial … for a new nonpeptide somatostatin receptor agonist. Crinetics Pharmaceuticals, …

… the go-to second-line treatment after somatostatin analog progression, though there …

… have responded to and tolerated treatment with somatostatin analogs. “Oczyesa is the … acromegaly comprises of seven clinical trials, including four phase 1 studies … and commercializing innovative, long-acting medicines for improving the lives of …

Panelists discuss how initial treatment recommendations require a … disease grade and distribution, somatostatin receptor status, and patient factors … , with somatostatin analogs typically serving as first … PROMID and CLARINET trials.

Panelists discuss how treatment decisions after progression on first-line somatostatin analog therapy … kinase inhibitors), or local-regional treatments.